

DEPARTMENT OF THE AIR FORCE

HEADQUARTERS UNITED STATES AIR FORCE WASHINGTON DC

AUG 2 4 2009

MEMORANDUM FOR ALMAJCOM/SG

FROM: HQ USAF/SG3

110 Luke Avenue, Room 400 Bolling AFB, DC 20032-7050

SUBJECT: Update to Clinical Policy for Administration of the Anthrax Vaccine Adsorbed

(AVA)

Recent changes regarding the administration of the AVA have prompted the Assistant Secretary of Defense for Health Affairs (ASD(HA)) to update the clinical policy related to this vaccine. That policy, which consolidates and replaces several legacy anthrax vaccine policies, is attached to this memo and updates the clinical administration only. It does not change the personnel who receive the vaccine as identified in the USD (P&R) Memo, "Implementation of the Anthrax Vaccine Immunization Program," 6 Dec 06.

Clinical issues covered in the new policy include:

- a. The recent change in dosage schedule, (from a 6-shot series to a 5-shot series)
- b. Injection site selection, (subcutaneous to intramuscular)
- c. Medical screening and education material, (including pregnancy screening)
- d. Medical exemptions and adverse event management

My POC for this action is Lt Col Michael Lundy, AFMSA/SG3PM, (202) 404-2735, DSN 297-2735, or Michael.Lundy@Pentagon.af.mil.

TIMOTHY C. JEX, Colonel, USAF, MC, CFS Deputy Assistant Surgeon General, Health Care Operations Office of the Surgeon General

Attachment: ASD/HA Memo, 31 Jul 09